UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 16, 2020
ENZOLYTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
333-148425 |
|
30-0808561 |
|
(state or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
2000 N. Sentra Express Way
Unit 104
Plano, Texas 75074
(address of principal executive offices) (zip code)
120 W. Pomona Avenue
Monrovia, CA 91016
(former address)
(972) 292-9414
(registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item 7.01 Regulation FD Disclosure.
On April 16, 2020, Enzolytics, Inc., (the “Company”) issued a press release to update shareholders on the current corporate initiatives.
In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in Exhibit 99.1 hereto are deemed to be “furnished” and shall not be deemed to be “filed” for purposes of the Exchange Act. The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.
Safe Harbor
This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.
Item 8.01 Other Events.
On April 16, 2020, the Company announced its new physical address and telephone number
2000 N. Sentra Express Way
Unit 104
Plano, Texas 75074
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits: The following exhibits are filed with this report:
|
Exhibit No. |
Description |
|
Press Release dated April 16, 2020 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: April 16, 2020 |
|
|
|
|
|
Enzolytics, Inc |
|
|
|
|
|
|
By: |
/s/Harry Zhabilov |
|
|
Name: |
Harry Zhabilov |
|
|
Title: |
President and CEO |
|
|
|
|
Exhibit 99.1
Enzolytics-News 4-16-2020
Plano, TX., April 16, 2020 /-- Enzolytics- (OTC Pink Sheet-ENZC) is pleased to update shareholders on the current corporate initiatives. The company has retained SEC counsel for the purpose of updating all corporate information, financials and to bring the company current from a public company perspective and allow the achievement of the company objectives.
The immediate goals include:
Regain Current Status with OTC Markets
Open operation in the Dallas, Tx area where the company has relocated
Identify a CMO, Contract Manufacturing Organization, to produce the validation batch for Immunotech Laboratories BG-Europe.
Assist Immunotech Laboratories BG-Europe in the registration of ImmunH as an Immunomodulator for HIV treatment.
Further our development in North America of our Flagship HIV immune treatment compound IPF
As it relates to the CMO and production of the initial validation batch of our lead product ITV-1, which will be marketed in Europe as ImmunH through our partner, Immunotech Laboratories BG-Europe. This is for the treatment of HIV/Aids, and the validation batch production is for the purpose of Phase IV, as required by the regulatory agencies as part of the mass use permitting process. Upon a successful validation batch, the intention is for full commercialization in Eastern Europe initially, then expansion to additional markets. Enzolytics owns 49% of Immunotech Laboratories BG-Europe.
The company has made updates to its corporate website , www.enzolytics.com, and will continue to do so to provide further information to our shareholders.
About ENZOLYTICS;
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of HIV/AIDS. Enzolytics is committed to the betterment of health for all mankind and exploring/developing additional applications of its novel immunotherapy compounds to that end.
Enzolytics flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.
While Enzolytics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests.
Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech or any other person that the objectives and plans of Enzolytics will be achieved should not regard the forward-looking statements as a representation.
IR Contact:
Enzolytics, Inc.
Phone: (972) 292-9414
Fax: (972)-292-9414